Fred Montgomery has spent the last 28 years developing and patenting nitric oxide delivery system technology that led to the commercialization of nitric oxide therapy. He led the development of the INOvent delivery system for Datex-Ohmeda, which in 2000 was the first FDA 510(k) cleared nitric oxide delivery system that led to the commercial marketing of inhaled nitric oxide therapy in 2000. He established the Medical Device Group at INO Therapeutics, which developed the INOmax DS and INOmax DSIR products, the leading nitric oxide delivery systems in the United States to this day. Dr. Montgomery left Ikaria (formerly INO Therapeutics) in 2011 and cofounded NitricGen Inc. He received his Doctor of Philosophy degree from the University of Salford, England and his Master of Business Administration from the University of Bradford, England.